SOPHiA GENETICS (SOPH) Set to Release Quarterly Earnings on Tuesday

SOPHiA GENETICS (NASDAQ:SOPH) is projected to issue its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect SOPHiA GENETICS to announce earnings of ($0.1980) per share and revenue of $24.03 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. On average, analysts expect SOPHiA GENETICS to post ($0.77) EPS for the current fiscal year and ($0.31) EPS for the next fiscal year.

SOPHiA GENETICS Stock Up 2.3%

Shares of SOPH opened at $7.52 on Tuesday. The firm has a market cap of $630.85 million, a P/E ratio of -6.54 and a beta of 0.95. SOPHiA GENETICS has a 12-month low of $3.83 and a 12-month high of $8.98. The company’s 50-day moving average price is $7.89 and its 200 day moving average price is $5.90. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58.

Insider Activity at SOPHiA GENETICS

In related news, CEO Ross Muken sold 9,838 shares of the business’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.13, for a total transaction of $79,982.94. Following the completion of the transaction, the chief executive officer directly owned 660,391 shares of the company’s stock, valued at $5,368,978.83. The trade was a 1.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Chairman Jurgi Camblong sold 40,172 shares of the business’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.13, for a total value of $326,598.36. Following the transaction, the chairman directly owned 3,395,650 shares of the company’s stock, valued at $27,606,634.50. The trade was a 1.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 250,662 shares of company stock worth $1,942,499. Company insiders own 4.88% of the company’s stock.

Wall Street Analysts Forecast Growth

SOPH has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of SOPHiA GENETICS in a research note on Monday, October 12th. BTIG Research increased their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, October 15th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, SOPHiA GENETICS presently has a consensus rating of “Hold” and an average target price of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a healthcare technology company that develops data-driven solutions for genomic medicine. Its cloud-based platform uses artificial intelligence, machine learning and advanced analytics to help healthcare organizations analyze and interpret complex biological and clinical data.

The company’s primary offering, the SOPHiA DDM platform, supports next-generation sequencing workflows, including data management, quality control, genomic analysis, variant interpretation and reporting.